Gatifloxacin sesquihydrate (CAS 180200-66-2)

Gatifloxacin sesquihydrate, a fluoroquinolone antibiotic, has been extensively studied in scientific research for its antimicrobial properties and mechanisms of action. Its mechanism primarily involves inhibition of bacterial DNA gyrase and topoisomerase IV, essential enzymes involved in DNA replication and repair processes in bacteria. By targeting these enzymes, gatifloxacin disrupts DNA synthesis and leads to bacterial cell death. Research investigations have focused on elucidating the structural basis of gatifloxacin′s interaction with DNA gyrase and topoisomerase IV, providing insights into its high potency and broad-spectrum activity against various bacterial pathogens, including gram-positive and gram-negative bacteria. Furthermore, studies have explored the mechanisms underlying bacterial resistance to gatifloxacin, highlighting the importance of understanding resistance mechanisms for developing strategies to combat antimicrobial resistance. Additionally, gatifloxacin sesquihydrate has been utilized in research aimed at exploring novel drug delivery systems and formulations to enhance its efficacy and bioavailability. Its role as a valuable tool in microbiology and pharmaceutical research underscores gatifloxacin sesquihydrate′s significance in advancing our understanding of antimicrobial pharmacology and combating infectious diseases.